BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bertin D, Brodovitch A, Beziane A, Hug S, Bouamri A, Mege JL, Heim X, Bardin N. Anticardiolipin IgG Autoantibody Level Is an Independent Risk Factor for COVID-19 Severity. Arthritis Rheumatol 2020;72:1953-5. [PMID: 32564467 DOI: 10.1002/art.41409] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Bertin D, Brodovitch A, Lopez A, Arcani R, Thomas GM, Beziane A, Weber S, Babacci B, Heim X, Rey L, Leone M, Mege JL, Bardin N. Anti-cardiolipin IgG autoantibodies associate with circulating extracellular DNA in severe COVID-19. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-15969-y] [Reference Citation Analysis]
2 Bertin D, Kaphan E, Weber S, Babacci B, Arcani R, Faucher B, Ménard A, Brodovitch A, Mege JL, Bardin N. Persistent IgG anticardiolipin autoantibodies are associated with post-COVID syndrome. Int J Infect Dis 2021;113:23-5. [PMID: 34614444 DOI: 10.1016/j.ijid.2021.09.079] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhu Y, Zhong J, Dong L. Epidemiology and Clinical Management of Rheumatic Autoimmune Diseases in the COVID-19 Pandemic: A Review. Front Med (Lausanne) 2021;8:725226. [PMID: 34490312 DOI: 10.3389/fmed.2021.725226] [Reference Citation Analysis]
4 Karami Fath M, Jahangiri A, Ganji M, Sefid F, Payandeh Z, Hashemi ZS, Pourzardosht N, Hessami A, Mard-Soltani M, Zakeri A, Rahbar MR, Khalili S. SARS-CoV-2 Proteome Harbors Peptides Which Are Able to Trigger Autoimmunity Responses: Implications for Infection, Vaccination, and Population Coverage. Front Immunol 2021;12:705772. [PMID: 34447375 DOI: 10.3389/fimmu.2021.705772] [Reference Citation Analysis]
5 Foret T, Dufrost V, Salomon Du Mont L, Costa P, Lefevre B, Lacolley P, Regnault V, Zuily S, Wahl D. Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders? Curr Rheumatol Rep 2021;23:65. [PMID: 34218350 DOI: 10.1007/s11926-021-01029-3] [Reference Citation Analysis]
6 Favaloro EJ, Henry BM, Lippi G. COVID-19 and Antiphospholipid Antibodies: Time for a Reality Check? Semin Thromb Hemost 2021. [PMID: 34130340 DOI: 10.1055/s-0041-1728832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kantarcioglu B, Iqbal O, Walenga JM, Lewis B, Lewis J, Carter CA, Singh M, Lievano F, Tafur A, Ramacciotti E, Gerotziafas GT, Jeske W, Fareed J. An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination. Clin Appl Thromb Hemost 2021;27:10760296211021498. [PMID: 34060379 DOI: 10.1177/10760296211021498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ghosh R, Roy D, Mandal A, Pal SK, Chandra Swaika B, Naga D, Pandit A, Ray BK, Benito-León J. Cerebral venous thrombosis in COVID-19. Diabetes Metab Syndr 2021;15:1039-45. [PMID: 34015627 DOI: 10.1016/j.dsx.2021.04.026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
9 Taha M, Samavati L. Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review. RMD Open 2021;7:e001580. [PMID: 33958439 DOI: 10.1136/rmdopen-2021-001580] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
10 Gette M, Fernandes S, Marlinge M, Duranjou M, Adi W, Dambo M, Simeone P, Michelet P, Bruder N, Guieu R, Fromonot J. Predict Score: A New Biological and Clinical Tool to Help Predict Risk of Intensive Care Transfer for COVID-19 Patients. Biomedicines 2021;9:566. [PMID: 34070021 DOI: 10.3390/biomedicines9050566] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Trahtemberg U, Rottapel R, Dos Santos CC, Slutsky AS, Baker A, Fritzler MJ. Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients. Ann Rheum Dis 2021;80:1236-40. [PMID: 33903092 DOI: 10.1136/annrheumdis-2021-220206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
12 Ramos-Casals M, Brito-Zerón P, Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat Rev Rheumatol 2021;17:315-32. [PMID: 33903743 DOI: 10.1038/s41584-021-00608-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
13 Vollmer O, Tacquard C, Dieudonné Y, Nespola B, Sattler L, Grunebaum L, Gies V, Radosavljevic M, Kaeuffer C, Hansmann Y, Weber JC, Martin T, Arnaud L, Morel O, Guffroy A, Collange O, Mertes PM, Korganow AS, Delabranche X, Poindron V. Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent. Autoimmun Rev 2021;20:102822. [PMID: 33872769 DOI: 10.1016/j.autrev.2021.102822] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
14 Frapard T, Hue S, Rial C, Prost N, Mekontso Dessap A. Antiphospholipid Autoantibodies and Thrombosis in Patients With COVID‐19: Comment on the Article by Bertin et al. Arthritis Rheumatol 2021;73:897-9. [DOI: 10.1002/art.41634] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
15 Tang KT, Hsu BC, Chen DY. Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review. Front Immunol 2021;12:645013. [PMID: 33777042 DOI: 10.3389/fimmu.2021.645013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
16 Anaya JM, Monsalve DM, Rojas M, Rodríguez Y, Montoya-García N, Mancera-Navarro LM, Villadiego-Santana AM, Rodríguez-Leguizamón G, Acosta-Ampudia Y, Ramírez-Santana C. Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID-19. J Transl Autoimmun 2021;4:100091. [PMID: 33681751 DOI: 10.1016/j.jtauto.2021.100091] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
17 Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 2021;20:102792. [PMID: 33610751 DOI: 10.1016/j.autrev.2021.102792] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 26.0] [Reference Citation Analysis]
18 Gao ZW, Zhang HZ, Liu C, Dong K. Autoantibodies in COVID-19: frequency and function. Autoimmun Rev 2021;20:102754. [PMID: 33476817 DOI: 10.1016/j.autrev.2021.102754] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
19 Devaux CA, Camoin-Jau L, Mege JL, Raoult D. Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ? J Microbiol Immunol Infect 2021;54:37-45. [PMID: 33500211 DOI: 10.1016/j.jmii.2020.12.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Gautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, Leone M, La Scola B, Devaux C, Gaubert JY, Mege JL, Vitte J, Melenotte C, Rolain JM, Parola P, Lagier JC, Brouqui P, Raoult D. Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol 2020;16:1159-84. [PMID: 33356661 DOI: 10.1080/1744666X.2021.1847640] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
21 Novelli L, Motta F, De Santis M, Ansari AA, Gershwin ME, Selmi C. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 - A systematic review of the literature. J Autoimmun 2021;117:102592. [PMID: 33401171 DOI: 10.1016/j.jaut.2020.102592] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
22 Dauby N, Catteau L, Hautekiet J, Montourcy M, Bottieau E, Goetghebeur E, Van Beckhoven D. Reply to 'Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality'. Int J Antimicrob Agents 2021;57:106261. [PMID: 33321211 DOI: 10.1016/j.ijantimicag.2020.106261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 El Hasbani G, Taher AT, Jawad A, Uthman I. COVID-19, Antiphospholipid Antibodies, and Catastrophic Antiphospholipid Syndrome: A Possible Association? Clin Med Insights Arthritis Musculoskelet Disord 2020;13:1179544120978667. [PMID: 33328777 DOI: 10.1177/1179544120978667] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
24 Raoult D. Rational for meta-analysis and randomized treatment: the COVID-19 example. Clin Microbiol Infect 2021;27:6-8. [PMID: 33098998 DOI: 10.1016/j.cmi.2020.10.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
25 Pimentel LL, Rodríguez-Alcalá LM. Cholesterol, inflammation, and phospholipids: COVID-19 share traits with cardiovascular disease. Biochim Biophys Acta Mol Cell Biol Lipids 2021;1866:158839. [PMID: 33080357 DOI: 10.1016/j.bbalip.2020.158839] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Pineton de Chambrun M, Frere C, Miyara M, Amoura Z, Martin-Toutain I, Mathian A, Hekimian G, Combes A. Response to Letter: 'Reply to "High frequency of antiphospholipid antibodies in critically ill COVID-19 patients: a link with hypercoagulability?"'. J Intern Med 2021;289:427-9. [PMID: 32772406 DOI: 10.1111/joim.13166] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Nasonov EL, Beketova TV, Reshetnyak TM, Lila AM, Ananieva LP, Lisitsyna TA, Soloviev SK. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Naučno-praktičeskaâ revmatologiâ 2020;58:353-67. [DOI: 10.47360/1995-4484-2020-353-367] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 7.5] [Reference Citation Analysis]
28 Melenotte C, Silvin A, Goubet AG, Lahmar I, Dubuisson A, Zumla A, Raoult D, Merad M, Gachot B, Hénon C, Solary E, Fontenay M, André F, Maeurer M, Ippolito G, Piacentini M, Wang FS, Ginhoux F, Marabelle A, Kroemer G, Derosa L, Zitvogel L. Immune responses during COVID-19 infection. Oncoimmunology 2020;9:1807836. [PMID: 32939324 DOI: 10.1080/2162402X.2020.1807836] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
29 Robba C, Battaglini D, Pelosi P, Rocco PRM. Response to letter to the editor: catastrophic antiphospholipid antibody syndrome and multiple organ dysfunctions in critically ill patients with COVID-19. Expert Rev Respir Med 2020;14:1073-4. [PMID: 32713214 DOI: 10.1080/17476348.2020.1802191] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Mathian A, Pineton De Chambrun M, Combes A, Amoura Z. Response to: 'Presence of anti-phospholipid antibodies in COVID-19: a case series study' by Amezcua-Guerra et al. Ann Rheum Dis 2021;80:e74. [PMID: 32753427 DOI: 10.1136/annrheumdis-2020-218145] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Ahmed S, Zimba O, Gasparyan AY. Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad. Clin Rheumatol. 2020;39:2529-2543. [PMID: 32654082 DOI: 10.1007/s10067-020-05275-1] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 31.0] [Reference Citation Analysis]